Information  X 
Enter a valid email address

Target Healthcare (THRL)

  Print      Mail a friend

Monday 15 October, 2018

Target Healthcare

Publication of Supplementary Prospectus

RNS Number : 1127E
Target Healthcare REIT Limited
15 October 2018
 

TARGET HEALTHCARE REIT LIMITED 

15 OCTOBER 2018

PUBLICATION OF SUPPLEMENTARY PROSPECTUS

Target Healthcare REIT Limited (the "Company") has today published a supplementary prospectus approved by the UK Listing Authority. The publication of the supplementary prospectus is a regulatory requirement under the Prospectus Rules following the publication of the Company's annual accounts for the year ended 30 June 2018.

The supplementary prospectus is supplemental to, and should be read in conjunction with, the prospectus published by the Company on 1 February 2018 in relation to the issue of ordinary shares pursuant to an initial placing, offer for subscription, open offer and placing programme.

A copy of the supplementary prospectus will shortly be available for inspection at the National Storage Mechanism which is located at http://www.morningstar.co.uk/uk/NSM

The supplementary prospectus is also available in electronic form on the Company's website at www.targethealthcarereit.co.uk and available for collection during normal business hours on any day (Saturday, Sunday and public holidays excepted) until 31 January 2019 at the offices of Dickson Minto W.S., Broadgate Tower, 20 Primrose Street, London EC2A 2EW.

 

Target Fund Managers Limited

 

 

Kenneth MacKenzie

 

01786 845 912

 

 

 

Stifel Nicolaus Europe Limited

 

 

Mark Young

[email protected]

+44 20 7710 7600

Neil Winward

[email protected]

+44 20 7710 7600

Tom Yeadon

[email protected]

+44 20 7710 7600

 

 

 

Maitland Administration Services (Scotland) Limited

 

 

Martin Cassels

[email protected]

0131 550 3760

 

 

 

FTI Consulting

 

 

Dido Laurimore

[email protected]

0203 727 1000

Claire Turvey

 

 

Richard Gotla

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
PSPBRBDGSGBBGIU

a d v e r t i s e m e n t